ArticleAlimentary pharmacology & therapeutics2023
Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD).
Article in Alimentary pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2026Guideline
- Progress and hotspot of diet or exercise therapy in the treatment of non-alcoholic fatty liver disease.Frontiers in nutrition · 2024Pooled it
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Obesity facts · 2024Guideline
- Dietary strategies in non-alcoholic fatty liver disease patients: From evidence to daily clinical practice, a systematic review.United European gastroenterology journal · 2023Pooled it
- Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis.Liver international : official journal of the International Association for the Study of the Liver · 2024Trial
- Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.Journal of gastroenterology and hepatology · 2026Article
- Lifespan approaches for the prevention and management of steatotic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Association Between Cardiometabolic Index and Liver Fibrosis: Mediation Analysis of Oxidative Stress Factors.Anatolian journal of cardiology · 2026Article
- Association of the C-reactive protein-triglyceride-glucose index with liver disease risk: findings from a nationwide Chinese cohort.BMC gastroenterology · 2026Article
- Physical activity and advanced fibrosis in MASLD, MetALD, and ALD in a nationally representative cohort: NHANES 2017-2020.Hepatology communications · 2025Article
- Association between cardiometabolic index and cardiometabolic multimorbidity in non-alcoholic fatty liver disease patients: evidence from a cross-sectional study.Scientific reports · 2025Article
- Association between questionnaire- and accelerometer-measured physical activity and incidence of cardiovascular disease in subjects with metabolic dysfunction-associated steatotic liver disease.American journal of preventive cardiology · 2025Article
- U-shaped association of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with NAFLD: results from the NHANES database prospective cohort study.BMC gastroenterology · 2025Article
- Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD.Communications medicine · 2025Article
- The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hepatic steatosis and liver fibrosis among US adults based on NHANES.Scientific reports · 2025Article
- Associations of physical activity type, intensity, and frequency with subclinical hypothyroidism: a cross-sectional analysis of NHANES 2007-2012.Frontiers in public health · 2025Article
- Association between eGDR and MASLD and liver fibrosis: a cross-sectional study based on NHANES 2017-2023.Frontiers in medicine · 2025Article
- Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective.Hepatology international · 2024Review
- MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.Hepatology international · 2024Review
- Low muscle quality index is associated with increased risk of advanced fibrosis in adult patients with nonalcoholic fatty liver disease: NHANES 2011-2014.Scientific reports · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.
aimTo investigate association between LTPA and reduction in all-cause mortality among adults with NAFLD.
methodsWe used NHANES (1999-2006) self-reported PA data for adults (≥40 years) with mortality follow-up through December 31, 2015. US-Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.
resultsNAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow-up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities-adjusted model, adults with NAFLD who reported ≥50% of their total PA as vigorous activity had a 56% reduction in all-cause mortality risk (HR:0.44, 95%CI: 0.25-0.76) and cancer-specific mortality risk (HR: 0.21, 0.06-0.66) but not cardiac-specific mortality (p > 0.05) compared to adults with NAFLD who did not report any LTPA. This association remained significant even among adults with NAFLD who met the recommended minimal PA, among adults with NAFLD who reported any LTPA, and among adults with NAFLD who had metabolic abnormalities and in sensitivity analysis.
conclusionsEngaging in vigorous activity is beneficial for adults with NAFLD - especially those with metabolic abnormalities.
Indexed as
Identifiers
36380111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.